Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future | Mariani and Venuti Journal ofTranslational Medicine 2010 8 105 http content 8 1 105 JOURNAL OF TRANSLATIONAL MEDICINE REVIEW Open Access HPV vaccine an overview of immune response clinical protection and new approaches for the future Luciano Mariani1 Aldo Venuti2 Abstract Although long-term protection is a key-point in evaluating HPV-vaccine over time there is currently inadequate information on the duration of HPV vaccine-induced immunity and on the mechanisms related to the activation of immune-memory. Longer-term surveillance in a vaccinated population is needed to identify waning immunity evaluating any requirements for booster immunizations to assess vaccine efficacy against HPV-diseases. Current prophylactic vaccines have the primary end-points to protect against HPV-16 and 18 the genotypes more associated to cervical cancer worldwide. Nevertheless data from many countries demonstrate the presence at significant levels of HPVs that are not included in the currently available vaccine preparations indicating that these vaccines could be less effective in a particular area of the world. The development of vaccines covering a larger number of HPVs presents the most complex challenge for the future. Therefore long term immunization and cross-protection of HPV vaccines will be discussed in light of new approaches for the future. Introduction The nature of antibody responses and duration following HPV vaccination plays a key role in long-term protection against papillomavirus infection. The importance of vigorous and prolonged immune protection over time is related to the following issues 1. the risk of HPV-infection remains as long as women remain sexually active at least 70-80 of risk during their lifetime the rate of prevalence and incidence of high-risk HPV-infection is well documented in women over 26 yrs 1 2 . Furthermore a population-based cohort study in Costa Rica showed that type-specific persistence increases with age 3 . .
